Edition:
India

People: Concert Pharmaceuticals Inc (CNCE.OQ)

CNCE.OQ on NASDAQ Stock Exchange Global Market

10.80USD
20 Sep 2019
Change (% chg)

$-0.08 (-0.74%)
Prev Close
$10.88
Open
$10.88
Day's High
$10.91
Day's Low
$10.48
Volume
140,421
Avg. Vol
52,065
52-wk High
$17.80
52-wk Low
$9.23

Hutt, Peter 

Mr. Peter Barton Hutt is the Independent Director of Concert Pharmaceuticals Inc. Mr. Hutt has served as a member of our Board of Directors since December 2006. Mr. Hutt has practiced law at Covington & Burling LLP, specializing in food and drug law, since 1960 (except for the period from 1971 to 1975) and currently serves as senior counsel. From 1971 to 1975, he was Chief Counsel for the Food and Drug Administration. Mr. Hutt is a member of the board of directors of Flex Pharma, Inc., Moderna, Inc., Immunomedics, Inc. and Q Therapeutics, Inc., each of which is a public biotechnology company, as well as numerous private companies. During the last five years, Mr. Hutt also served as a member of the board of directors of BIND Therapeutics, Inc., Seres Health, Inc., Xoma Ltd., DBV Technologies SA, a public biotechnology company, and Momenta Pharmaceuticals, Inc., a public biotechnology company. Mr. Hutt received a B.A. from Yale University, an LL.B. from Harvard Law School and an LL.M. from New York University School of Law. We believe Mr. Hutt’s extensive knowledge of regulatory and legal issues related to drug development and his service on numerous boards of directors allow him to be a key contributor to our Board of Directors.

Basic Compensation

Total Annual Compensation, USD 47,573
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 133,748
Fiscal Year Total, USD 181,321

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Richard Aldrich

205,613

Roger Tung

4,607,850

Marc Becker

2,450,530

Nancy Stuart

1,908,030

James Cassella

1,960,240

Thomas Auchincloss

205,613
As Of  31 Dec 2018